NunaBio, a pioneering life sciences spin-out from Newcastle, has recently secured £810,000 in investment. This latest funding round was led by Northstar Ventures with substantial contributions from existing investors.
NunaBio is poised to make significant strides in the life sciences sector with its cutting-edge DNA synthesis technologies. The company, founded by Dr Andrew Pike and Dr Eimer Tuite, has developed unique methods that allow for rapid, scalable, and cost-effective DNA production. This technological advancement addresses the burgeoning demand in the fields of gene therapy, diagnostics, and biomarker development.
The investment marks the first instance of cooperation between the Northstar EIS Growth Fund and the North East Innovation Fund, backed by the European Regional Development Fund. This collaboration exemplifies the importance of cooperative funding to fuel innovation and growth in pivotal sectors.
The collaborative approach in securing investment signifies a robust trust from investors in NunaBio’s vision and technological prowess.
Investment director at Northstar Ventures, Alex Buchan, has emphasised the potential global impact of NunaBio’s products. His statement reflects a broad recognition of the company’s capabilities and its role in addressing global scientific challenges.
Overall, the strategic investments and developmental focus positions NunaBio for exponential growth.
Such alliances not only provide financial backing but also strategic insight, reinforcing NunaBio’s innovative edge in the competitive landscape.
NunaBio remains committed to its path of innovation. The recent funding milestone is demonstrative of its capabilities and its trajectory towards becoming a leader in the life sciences field.
The investment in NunaBio highlights a significant endorsement of its innovative DNA synthesis technology. With strategic funding, the company’s impact on life sciences is poised to grow, contributing towards global advancements in healthcare and biotechnology.
